Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center talks about using Osimertinib in first line and possible shift to old practice afterwards. Osimertinib with positive data in the first line setting is very promising. Although FDA approval for Osimertinib is still pending, doctors can shift now to using it in the front-line setting based on the NCCN guidelines.
This is already been adapted and according to available data, Osimertinib is a superior drug. So, the question now would be on what to use in the second and third line setting. Dr. Rudin said that patients might end up going back to the traditional first-line therapy – platinum-based doublet chemotherapy.
Advertisement